fluvoxamine / Generic mfg. - LARVOL DELTA

Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open-Label Study. (PubMed, Pharmacol Res Perspect) - "These data suggest a significant drug-drug interaction between savolitinib and the strong CYP1A2 inhibitor, fluvoxamine, and that CYP1A2 is involved in the formation of M2, but not M3. No new safety concerns were observed when savolitinib was administered alone or with twice-daily fluvoxamine."

Journal • P1 data • PK/PD data • CYP1A2

Anti-inflammatory action of fluvoxamine in an endotoxin-induced uveitis rat model: Histopathological evidence. (PubMed, Mol Vis) - "Histopathologic scores confirmed significant retinal changes in the EIU group compared to the others (p < 0.001). FVX significantly reduced clinical signs of ocular inflammation and mitigated histopathologic damage in the cornea, limbus, and retina."

Journal • Preclinical • Hematological Disorders • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

Fluvoxamine mitigates bleomycin-induced pulmonary fibrosis in mice (ERS 2026) - "Based on our preclinical data, S1R may be a novel and effective drug target for treating pulmonary fibrosis."

Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • TGFB1

Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system. (PubMed, Eur Arch Psychiatry Clin Neurosci) - "SSRIs showed homogeneous adverse event reporting patterns, with relatively few differences in disproportional reporting between individual drugs. These results reinforce the importance of continuous pharmacovigilance monitoring."

Adverse events • Journal • CNS Disorders • Mental Retardation • Pain • Psychiatry • ROR1

Pharmacological insights into fluvoxamine maleate: σ1 receptor agonism, multimodal mechanisms, and therapeutic repositioning. (PubMed, Curr Opin Pharmacol) - "Fluvoxamine demonstrates one of the highest affinities for σ1R among SSRIs, exceeding those of sertraline and fluoxetine, via dissociating σ1R from BiP chaperones to improve protein refolding and cellular resilience. Preclinical experiments illustrate its inhibition of unfolded protein response indicators, reinstatement of glutamatergic transmission, and stimulation of parvalbumin interneurons, resulting in antipsychotic-like effects in schizophrenia and neuroprotection against ketamine-induced impairments...σ1R agonism is fundamental to its effectiveness in disorders caused by ER stress, such as schizophrenia and tardive dyskinesia, and in neuropsychiatric sequelae associated with protracted COVID. Clinical translation encounters obstacles in dose optimization and σ1R selectivity; yet, current studies highlight its multimodal efficacy in neurodegeneration, fibrosis, and psychopharmacology."

Journal • Review • CNS Disorders • Depression • Fibrosis • Immunology • Inflammation • Mood Disorders • Movement Disorders • Novel Coronavirus Disease • Obsessive-Compulsive Disorder • Psychiatry • Schizophrenia

Evaluating Caffeine Intake and Reduction in Patients with Lower Urinary Tract Symptoms (LUTS). (PubMed, Eur Urol Focus) - "This includes certain medications, having recently stopped smoking, or liver problems. Working out your total caffeine intake and reducing it gradually can help ease these symptoms."

Journal • Hepatology • Overactive Bladder • Tobacco Cessation • Urinary Incontinence • Urology

LYMPHODEP: Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Germans Trias i Pujol Hospital | Trial completion date: Jul 2027 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jun 2026 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK. (PubMed, Lancet Psychiatry) - "CYP2D6 PM status was consistently associated with increased risk of venlafaxine treatment failure in two large, real-life cohorts, suggesting that pre-emptive genotyping could facilitate personalised venlafaxine therapy."

Journal • Observational data • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Psychiatry • CYP2C19

Serotonin Transporter and Organic Cation Transporter 3 Contribute to Basolateral Amygdala Serotonin Clearance and Recent Fear Memory Recall. (PubMed, ACS Chem Neurosci) - "The SSRI fluvoxamine prolonged serotonin clearance in BLA of wildtype mice and OCT3 knockdown mice to a similar degree, and this effect was lost in mice with SERT depletion. Behaviorally, depletion of SERT or OCT3 from serotonin neurons did not impact fear learning; however, depletion of SERT trended to attenuate cued fear memory, and depletion of OCT3 modestly attenuated cued and contextual fear memory. These findings indicate that OCT3 could serve as a novel therapeutic target for psychiatric disorders related to emotional dysregulation and encourage research into nonconventional treatments for these prevalent disorders."

Journal • CNS Disorders • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

CYP2D6 Allele and Metabolizer Phenotype Distribution in a Central Indian Depression Cohort: Interim Pharmacogenetic Findings (WFSBP 2026) - "These findings have direct implications for antidepressant prescribing. CYP2D6 PMs may experience higher exposure and adverse effects with paroxetine, fluvoxamine, venlafaxine, TCAs, and vortioxetine, while UMs risk subtherapeutic response. The substantial IM proportion may have altered dose requirements."

Biomarker • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • CYP2D6

"Prescribers Beware": a narrative review of dangerous drug-drug-interactions involving psychotropic medications. (PubMed, Eur J Clin Pharmacol) - "This review highlights specific drug-drug interaction combinations that are well supported by the literature and clinically actionable to avoid, helping clinicians recognize and prevent dangerous polypharmacy combinations during everyday clinical practice."

Journal • Review • Psychiatry

The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents. (PubMed, Front Pharmacol) - "In addition, this review summarizes other therapeutic candidates acting via distinct mechanisms, such as fluvoxamine, coenzyme Q10 combined with alpha-lipoic acid, astragalus root extracts, other medicinal herbs and traditional Chinese compound formulas. Post-COVID syndrome represents a complex public health challenge. Further in-depth mechanistic research and rational application of emerging technologies are still required to develop therapeutic strategies for preventing and alleviating the onset and progression of post-COVID syndrome."

Journal • Review • Fatigue • Inflammation • Metabolic Disorders • Novel Coronavirus Disease • NLRP3 • TLR4 • TLR7

Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. (PubMed, Focus (Am Psychiatr Publ)) - "In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (range of ORs 1·19-1·96), whereas fluoxetine, fluvoxamine, reboxetine, and trazodone were the least efficacious drugs (0·51-0·84). For acceptability, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine were more tolerable than other antidepressants (range of ORs 0·43-0·77), whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine had the highest dropout rates (1·30-2·32)...These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants. National Institute for Health Research Oxford Health Biomedical Research Centre and the Japan Society for the Promotion of Science.Appeared..."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Intrusive Mental Images Resembling Psychosis in a Patient With Obsessive-Compulsive Disorder. (PubMed, Cureus) - "Fluvoxamine 50-150 mg/day was associated with a subjective 10%-20% improvement without documented adverse effects; the treatment was later switched to fluoxetine because of cost-related factors. Long-term follow-up and standardized severity scores were unavailable. This case highlights the importance of assessing thought ownership, resistance, insight, conviction, and the anxiety-reducing function of rituals before labeling vivid intrusive mental images as hallucinations or delusions."

Journal • Asthma • CNS Disorders • Immunology • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Pulmonary Disease • Respiratory Diseases

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions of TPN171, a Novel Phosphodiesterase Type 5 Inhibitor. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "A physiologically based pharmacokinetic (PBPK) model was developed and validated using clinical DDI data for itraconazole (strong CYP3A4 inhibitor) and rifampin (strong CYP3A4 inducer). The model was then applied to predict DDIs with moderate (diltiazem, fluconazole) and mild (fluvoxamine) inhibitors, as well as moderate (efavirenz) and mild (zanubrutinib) inducers...These simulations indicate that strong and moderate CYP3A4 inhibitors and inducers significantly alter TPN171 exposure, whereas weak modulators have no clinically meaningful impact. These findings provide a scientific basis for dose recommendations when TPN171 is used with CYP3A4 modulators."

Journal • PK/PD data • Cardiovascular • Erectile Dysfunction • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Physiologically Based Pharmacokinetic (PBPK) Modeling of Antidepressants: A Scoping Review of Existing Models, Applications, and Software Tools. (PubMed, Clin Pharmacokinet) - "Paroxetine, fluvoxamine, and venlafaxine were most frequently modeled (n = 10 each), whereas few or no models exist for substances such as mirtazapine (n = 1) or milnacipran (n = 0). Although physiologically based pharmacokinetic models for antidepressants are increasingly available, they focus on a limited number of drugs and applications. Substantial evidence gaps remain, particularly for vulnerable patient populations."

Journal • PK/PD data • Review • Geriatric Disorders • Pediatrics

Pharmacovigilance Analysis of Bleeding Events Associated With Selective Serotonin Reuptake Inhibitors (SSRIs) Using the US Food and Drug Administration Adverse Event Reporting System (FAERS). (PubMed, Cureus) - "Bleeding event rates varied by SSRI: escitalopram (2.85%), citalopram (1.93%), paroxetine (1.29%), sertraline (1.25%), fluvoxamine (1.05%), and fluoxetine (1.02%)...Concomitant use of medications increasing bleeding risk was documented in 541 cases (9.7%), with antiplatelet agents being most frequent (246, 4.4%), followed by nonsteroidal anti-inflammatory drugs (NSAIDs) (143, 2.6%), direct oral anticoagulants (DOACs) (130, 2.3%), and warfarin (22, 0.4%)...There were differences in bleeding patterns within the FAERS data; however, these findings are descriptive and should not be interpreted as comparative risk differences. These findings underscore the importance of individualized risk assessment, careful medication reconciliation, and strengthened pharmacovigilance to support safer SSRI prescription in routine clinical practice."

Adverse events • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Hematological Disorders • Mood Disorders • Psychiatry • Subarachnoid Hemorrhage

Fluvoxamine combined with lenvatinib enhances anti-hepatocellular carcinoma immunity by promoting M1 macrophage and T-cell infiltration. (PubMed, Sci Rep) - "In vivo, it exerted more potent tumor growth inhibition without obvious toxicity, further downregulated PD-L1/VEGF, enhanced intra-tumoral T cell and M1 macrophage infiltration, and increased systemic T lymphocyte proportions. Fluvoxamine combined with lenvatinib exerts synergistic anti-HCC activity and is associated with enhanced antitumor immune infiltration, providing experimental evidence for novel clinical HCC combination therapies."

IO biomarker • Journal • Hepatocellular Cancer • Immunology • Oncology • Solid Tumor • BCL2 • CASP3 • MMP2 • STAT3

CYP3A-Mediated Metabolism of Zastaprazan in Humans and Associated Drug-Drug Interactions. (PubMed, Pharmaceutics) - "By integrating in vitro data, clinical pharmacokinetic data and clarithromycin coadministration DDI data, a physiologically based pharmacokinetic (PBPK) model was developed and validated. Simulations predicted significant DDIs with strong CYP3A inhibitor (ketoconazole), with AUC ratios of 3.80. Moderate inhibitors (fluconazole and fluvoxamine) caused mild increases (AUC ratios: 1.14-1.74). Conversely, strong and moderate CYP3A inducers, rifampicin and efavirenz, produced pronounced DDIs, with AUC ratios of 0.22 and 0.50, respectively...The PBPK simulations suggest that JP-1366 may be a moderately sensitive CYP3A substrate and a moderate inhibitor of sensitive CYP3A substrates, while its perpetrator DDI risk toward other major CYP pathways appears limited. These findings support caution or monitoring when JP-1366 is co-administered with strong CYP3A modulators or sensitive CYP3A substrates."

Journal • Gastroenterology • Gastroesophageal Reflux Disease • CYP1A2 • CYP2C9

Sex differences in antidepressant serum levels (CINP 2026) - " Serum levels of amitriptyline, nortriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine, imipramine, mirtazapine, paroxetine, sertraline, and venlafaxine, along with their active metabolites, were collected from the laboratory information system (GLIMS) database of the University Medical Centre Groningen (UMCG) between January 2016 and October 2024. Under current treatment guidelines, women are exposed to significantly higher antidepressant serum levels than men for citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, clomipramine, imipramine, nortriptyline, and venlafaxine. Subgroup analyses confirmed that the observed sex differences are unlikely to result from dosing practices but instead reflect sex differences in underlying mechanisms such as pharmacokinetic variations or sex-specific epigenetic regulation of hepatic drug-metabolizing enzymes. Whereas most antidepressants investigated are prescribed using standardized dosing regimens, dosing of..."

CNS Disorders • Depression • Mood Disorders • Psychiatry

Optimizing Mirtazapine Initial Dosing: A Population Analysis of the Effects of BMI, Paroxetine and Fluvoxamine. (PubMed, Drug Des Devel Ther) - "The developed PPK model accurately characterizes the pharmacokinetics of MTZ in Chinese patients, identifying BMI, paroxetine, and fluvoxamine as main factors influencing clearance. These findings provide a valuable reference for optimizing individualized MTZ dosing."

Journal • CNS Disorders • Depression • Genetic Disorders • Obesity • Psychiatry

ESPRIT: sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 (clinicaltrials.gov) - P3 | N=160 | Recruiting | Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2026 ➔ Jun 2026 | Trial primary completion date: Mar 2027 ➔ Dec 2027

Enrollment open • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Absence of pharmacovigilance signals for bleeding events associated with warfarin-SSRI drug interactions: a comparative analysis of FAERS and CVARD databases. (PubMed, Ther Adv Drug Saf) - "While the warfarin-fluvoxamine combination showed isolated positive signals in secondary models, the primary Ω shrinkage measure remained statistically nonsignificant (95% CI: encompassed zero). This study is a real-world pharmacovigilance investigation based on publicly accessible databases. As such, it does not involve a formal clinical trial, and therefore, no clinical trial registration number is applicable."

Adverse events • Journal • Cardiovascular • Psychiatry

Fluvoxamine and lycopene alleviate cisplatin-induced kidney fibrosis by modulating miR-21 and fibrotic signaling pathways. (PubMed, Sci Rep) - "FLV and LYC effectively attenuated Cis-induced kidney fibrosis through antioxidant, antiapoptotic, and antifibrotic mechanisms. These findings may provide a new therapeutic approach to counter Cis-induced nephrotoxicity in clinical settings."

IO biomarker • Journal • Fibrosis • Immunology • Oncology • BAX • MIR21 • SMAD3 • SMAD4 • TGFB1

Identification of efflux inhibitors through a drug repurposing strategy in Candida albicans. (PubMed, Front Cell Infect Microbiol) - "We further evaluated the potential adjuvant effect of these drugs on the activity of fluconazole. Fluorometric assays revealed amlodipine, fluvoxamine and fluoxetine as potential efflux inhibitors in C. albicans. These findings highlight the potential of these drugs to contribute to the research and development of new therapeutic alternatives aimed at combating antifungal resistance."

Journal • Infectious Disease